ConductScience.org, home
IL31: interleukin 31
API referenceFor AI assistants

Gene · 386653

Papers2,753

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

1 to 20 of 2,753

Download this page as JSON
TitleJournalYearPMIDFound bySource
Off-Label Uses of Nemolizumab: A Narrative Review.J Drugs Dermatol202642826149PubTator, text miningPubMed
Analytical standardization and inter-platform harmonization of immunoassay-based biomarkers in atopic dermatitis: Challenges and a roadmap for clinical laboratory implementation.Clin Chim Acta202642805450PubTator, text miningPubMed
Differential Expression of miR-146a, IL-31, and IL-33 in Osteoporosis and their Associations with Disease Severity.Comb Chem High Throughput Screen202642786842PubTator, text miningPubMed
EGR1 coordinates a nuclear IL-33-phosphorylated STAT3 transcriptional complex to promote IL31 expression in TLR1/2-activated keratinocytes.Biochem Biophys Res Commun202642748574PubTator, text miningPubMed
Herbal Extracts and Plant-Derived Bioactives in Atopic Dermatitis: Evidence, Mechanisms, Pediatric Safety, and Translational Priorities.Food Sci Nutr202642732250PubTator, text miningPubMed
Real-world effectiveness of a topical dihydroavenanthramide D formulation for chronic pruritus: A multicenter clinical study with molecular evidence of pruritogenic pathway modulation.Narra J202642724128PubTator, text miningPubMed
Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases.Allergy202642713891PubTator, text miningPubMed
Abrocitinib and dupilumab bridging therapy for bullous pemphigoid with insufficient response to initial corticosteroid therapy: a case report.Front Immunol202642707251PubTator, text miningPubMed
: Interleukin-31 in Atopic Dermatitis and Prurigo Nodularis: Pathophysiology, Neuroimmune Mechanisms, and Clinical Efficacy of Nemolizumab.J Drugs Dermatol202642696343PubTator, text miningPubMed
Randomized controlled study of nemolizumab in patients with chronic kidney disease-associated pruritus: NIKAIA-1.J Am Acad Dermatol202642680109PubTator, text miningPubMed
Targeting type 2 inflammation in dermatology: mechanisms and clinical implications.Front Immunol202642677114PubTator, text miningPubMed
Repositioning omalizumab in dermatology: emerging indications and mechanism-based therapeutic insights.Expert Opin Biol Ther202642664019PubTator, text miningPubMed
IL-4Rα antagonist (Stapokibart) in refractory palmoplantar pustulosis: a case report and literature review of Th2-targeted therapies.Front Immunol202642661770PubTator, text miningPubMed
Autosomal recessive OSMRβ deficiency: Connecting OSM and/or IL-31 with atopy.J Hum Immun202642639505PubTator, text miningPubMed
Cryo-EM structure of the interleukin-31 receptor complex defines non-canonical interactions that confer receptor specificity.J Biol Chem202642637078PubTator, text miningPubMed
The evaluation of cytokine profiles in atopic dermatitis patients treated with dupilumab: association with ocular complications.Front Immunol202642625606PubTator, text miningPubMed
Cancer-associated pruritus: Insights into its pathogenesis and management.J Invest Dermatol202642578899PubTator, text miningPubMed
Peripheral and central inflammation in progressive supranuclear palsy syndrome: an immunological and imaging neuroinflammation study.Front Immunol202642564111PubTator, text miningPubMed
Atopic Dermatitis Flare Following Initiation of Nemolizumab.J Drugs Dermatol202642555068PubTator, text miningPubMed
Time-of-day-dependent immune dynamics are associated with disease severity and therapeutic response in psoriasis.Br J Dermatol202642517573PubTator, text miningPubMed

gene-search-2026-11-11-0.2.0

Next page

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/genes/v1/386653/papers

API referenceFor AI assistants